SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma receives USFDA approval for generic Glumetza

02 Aug 2016 Evaluate

Sun Pharmaceutical Industries’ subsidiary has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Glumetza, Metformin Hydrochloride extended release tablets 500 mg and 1000 mg.

These Metformin Hydrochloride extended release tablets are therapeutic equivalents of Santarus Inc.’s Glumetza tablets. As per IMS MAT June 2016, these tablets have annual sales of approximately $1.2 billion in the US. The commercial launch of these tablets in the US is expected over the next few weeks.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma. Inds. Share Price

1904.65 33.10 (1.77%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: